Teladoc, Inc. (TDOC) Receives “Buy” Rating from Canaccord Genuity

Canaccord Genuity reissued their buy rating on shares of Teladoc, Inc. (NYSE:TDOC) in a report released on Wednesday, May 24th. The brokerage currently has a $34.00 price objective on the health services provider’s stock.

Several other brokerages have also recently issued reports on TDOC. Zacks Investment Research raised Teladoc from a sell rating to a hold rating in a research report on Thursday, May 11th. Craig Hallum cut Teladoc from a buy rating to a hold rating and raised their target price for the stock from $28.00 to $32.00 in a research report on Friday, May 12th. KeyCorp began coverage on Teladoc in a research report on Wednesday, May 17th. They issued an overweight rating and a $37.00 target price on the stock. TheStreet raised Teladoc from a d rating to a c- rating in a research report on Thursday, April 13th. Finally, Chardan Capital reissued a buy rating on shares of Teladoc in a research report on Monday, March 27th. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $31.31.

Teladoc (NYSE:TDOC) traded up 1.95% during midday trading on Wednesday, reaching $34.00. 996,659 shares of the company’s stock traded hands. Teladoc has a one year low of $12.31 and a one year high of $34.60. The stock’s 50 day moving average price is $29.48 and its 200-day moving average price is $23.00. The stock’s market cap is $1.85 billion.

Teladoc (NYSE:TDOC) last released its quarterly earnings data on Monday, May 8th. The health services provider reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.03. The company had revenue of $42.90 million during the quarter, compared to the consensus estimate of $42.22 million. Teladoc had a negative return on equity of 24.73% and a negative net margin of 53.58%. Teladoc’s revenue for the quarter was up 59.5% on a year-over-year basis. During the same period last year, the company earned ($0.40) EPS. Equities analysts predict that Teladoc will post ($0.88) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2017/06/16/teladoc-inc-tdoc-given-buy-rating-at-canaccord-genuity-updated-updated.html.

In related news, CEO Jason N. Gorevic sold 13,389 shares of the business’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $32.89, for a total value of $440,364.21. Following the transaction, the chief executive officer now directly owns 831,650 shares of the company’s stock, valued at approximately $27,352,968.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Jason N. Gorevic sold 19,991 shares of the business’s stock in a transaction that occurred on Tuesday, June 6th. The stock was sold at an average price of $32.89, for a total value of $657,503.99. Following the completion of the transaction, the chief executive officer now directly owns 831,650 shares in the company, valued at $27,352,968.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 232,480 shares of company stock worth $6,439,354. 5.94% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. US Bancorp DE boosted its position in Teladoc by 10.3% in the first quarter. US Bancorp DE now owns 4,617 shares of the health services provider’s stock worth $116,000 after buying an additional 433 shares in the last quarter. Jaffetilchin Investment Partners LLC increased its stake in Teladoc by 1.8% in the first quarter. Jaffetilchin Investment Partners LLC now owns 45,225 shares of the health services provider’s stock worth $1,131,000 after buying an additional 814 shares during the last quarter. Teachers Advisors LLC increased its stake in Teladoc by 5.3% in the fourth quarter. Teachers Advisors LLC now owns 35,205 shares of the health services provider’s stock worth $581,000 after buying an additional 1,759 shares during the last quarter. Legal & General Group Plc increased its stake in Teladoc by 66.3% in the first quarter. Legal & General Group Plc now owns 6,137 shares of the health services provider’s stock worth $154,000 after buying an additional 2,446 shares during the last quarter. Finally, American International Group Inc. increased its stake in Teladoc by 22.2% in the first quarter. American International Group Inc. now owns 14,575 shares of the health services provider’s stock worth $364,000 after buying an additional 2,644 shares during the last quarter. 94.61% of the stock is currently owned by institutional investors.

About Teladoc

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply